Prevalence and Phenotypes of APC and MUTYH Mutations in Patients with Multiple Colorectal Adenomas

Overview

Journal JAMA

Publisher American Medical Association

Specialty General Medicine

Date 2012 Aug 2

PMID 22851115

Citations 78

Authors

Shilpa Grover

Fay Kastrinos

Ewout W Steyerberg

E Francis Cook

Akriti Dewanwala

Lynn Anne Burbidge

Richard J Wenstrup

Sapna Syngal

Affiliations

Soon will be listed here.

Abstract

Context: Patients with multiple colorectal adenomas may carry germline mutations in the APC or MUTYH genes.

Objectives: To determine the prevalence of pathogenic APC and MUTYH mutations in patients with multiple colorectal adenomas who had undergone genetic testing and to compare the prevalence and clinical characteristics of APC and MUTYH mutation carriers.

Design, Setting, And Participants: Cross-sectional study conducted among 8676 individuals who had undergone full gene sequencing and large rearrangement analysis of the APC gene and targeted sequence analysis for the 2 most common MUTYH mutations (Y179C and G396D) between 2004 and 2011. Individuals with either mutation underwent full MUTYH gene sequencing. APC and MUTYH mutation prevalence was evaluated by polyp burden; the clinical characteristics associated with a pathogenic mutation were evaluated using logistic regression analyses.

Main Outcome Measure: Prevalence of pathogenic mutations in APC and MUTYH genes.

Results: Colorectal adenomas were reported in 7225 individuals; 1457 with classic polyposis (≥100 adenomas) and 3253 with attenuated polyposis (20-99 adenomas). The prevalence of pathogenic APC and biallelic MUTYH mutations was 95 of 119 (80% [95% CI, 71%-87%]) and 2 of 119 (2% [95% CI, 0.2%-6%]), respectively, among individuals with 1000 or more adenomas, 756 of 1338 (56% [95% CI, 54%-59%]) and 94 of 1338 (7% [95% CI, 6%-8%]) among those with 100 to 999 adenomas, 326 of 3253 (10% [95% CI, 9%-11%]) and 233 of 3253 (7% [95% CI, 6%-8%]) among those with 20 to 99 adenomas, and 50 of 970 (5% [95% CI, 4%-7%]) and 37 of 970 (4% [95% CI, 3%-5%]) among those with 10 to 19 adenomas. Adenoma count was strongly associated with a pathogenic mutation in multivariable analyses.

Conclusions: Among patients with multiple colorectal adenomas, pathogenic APC and MUTYH mutation prevalence varied considerably by adenoma count, including within those with a classic polyposis phenotype. APC mutations predominated in patients with classic polyposis, whereas prevalence of APC and MUTYH mutations was similar in attenuated polyposis. These findings require external validation.

Citing Articles

De novo familial adenomatous polyposis with germline double heterozygosity of APC/BRCA2: a case report and literature review.

Zhang T, Cai J, Li C, Xu Y, Xu Y Hered Cancer Clin Pract. 2025; 23(1):6.

PMID: 39985003 PMC: 11843810. DOI: 10.1186/s13053-025-00306-x.

Wnt Pathway-Targeted Therapy in Gastrointestinal Cancers: Integrating Benchside Insights with Bedside Applications.

Nayak A, Streiff H, Gonzalez I, Adekoya O, Silva I, Shenoy A Cells. 2025; 14(3).

PMID: 39936971 PMC: 11816596. DOI: 10.3390/cells14030178.

In Silico Deciphering of the Potential Impact of Variants of Uncertain Significance in Hereditary Colorectal Cancer Syndromes.

Fasano C, Lepore Signorile M, De Marco K, Forte G, Disciglio V, Sanese P Cells. 2024; 13(16.

PMID: 39195204 PMC: 11352798. DOI: 10.3390/cells13161314.

Exploring Familial Adenomatous Polyposis Through Radiology: A Case Series and Literature Review.

Rashi S, Seeni Mohamed A, Ramakrishnan K, Subramonian S, Udaya Bhanu V Cureus. 2024; 16(7):e64855.

PMID: 39156381 PMC: 11330316. DOI: 10.7759/cureus.64855.

Predictive modeling for the germline pathogenic variant of the APC gene in patients with adenomatous polyposis: proposing a new APC score.

Takao M, Yamaguchi T, Eguchi H, Suzuki O, Mori Y, Chika N Surg Today. 2024; 55(2):229-237.

PMID: 38970662 DOI: 10.1007/s00595-024-02894-y.

References

Venesio T, Molatore S, Cattaneo F, Arrigoni A, Risio M, Ranzani G . High frequency of MYH gene mutations in a subset of patients with familial adenomatous polyposis. Gastroenterology. 2004; 126(7):1681-5. DOI: 10.1053/j.gastro.2004.02.022. View

Sieber O, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips R . Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med. 2003; 348(9):791-9. DOI: 10.1056/NEJMoa025283. View

Farrington S, Tenesa A, Barnetson R, Wiltshire A, Prendergast J, Porteous M . Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet. 2005; 77(1):112-9. PMC: 1226182. DOI: 10.1086/431213. View

Balmana J, Stockwell D, Steyerberg E, Stoffel E, Deffenbaugh A, Reid J . Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA. 2006; 296(12):1469-78. DOI: 10.1001/jama.296.12.1469. View

Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A . Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 1991; 253(5020):665-9. DOI: 10.1126/science.1651563. View

Raedle J, Trojan J, Brieger A, Weber N, Schafer D, Plotz G . Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer. Ann Intern Med. 2001; 135(8 Pt 1):566-76. DOI: 10.7326/0003-4819-135-8_part_1-200110160-00007. View

Nielsen M, Hes F, Nagengast F, Weiss M, Mathus-Vliegen E, Morreau H . Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. Clin Genet. 2007; 71(5):427-33. DOI: 10.1111/j.1399-0004.2007.00766.x. View

Gismondi V, Meta M, Bonelli L, Radice P, Sala P, Bertario L . Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. Int J Cancer. 2004; 109(5):680-4. DOI: 10.1002/ijc.20054. View

Burt R, Barthel J, Dunn K, David D, Drelichman E, Ford J . NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw. 2010; 8(1):8-61. DOI: 10.6004/jnccn.2010.0003. View

10.

Pinol V, Castells A, Andreu M, Castellvi-Bel S, Alenda C, Llor X . Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005; 293(16):1986-94. DOI: 10.1001/jama.293.16.1986. View

11.

Balaguer F, Balmana J, Castellvi-Bel S, Steyerberg E, Andreu M, Llor X . Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology. 2007; 134(1):39-46. PMC: 2542581. DOI: 10.1053/j.gastro.2007.10.042. View

12.

Croitoru M, Cleary S, Berk T, Di Nicola N, Kopolovic I, Bapat B . Germline MYH mutations in a clinic-based series of Canadian multiple colorectal adenoma patients. J Surg Oncol. 2007; 95(6):499-506. DOI: 10.1002/jso.20724. View

13.

Giarola M, Stagi L, Presciuttini S, MONDINI P, Radice M, Sala P . Screening for mutations of the APC gene in 66 Italian familial adenomatous polyposis patients: evidence for phenotypic differences in cases with and without identified mutation. Hum Mutat. 1999; 13(2):116-23. DOI: 10.1002/(SICI)1098-1004(1999)13:2<116::AID-HUMU3>3.0.CO;2-2. View

14.

Fleischmann C, Peto J, Cheadle J, Shah B, Sampson J, Houlston R . Comprehensive analysis of the contribution of germline MYH variation to early-onset colorectal cancer. Int J Cancer. 2004; 109(4):554-8. DOI: 10.1002/ijc.20020. View

15.

Kinzler K, Nilbert M, Su L, Vogelstein B, Bryan T, Levy D . Identification of FAP locus genes from chromosome 5q21. Science. 1991; 253(5020):661-5. DOI: 10.1126/science.1651562. View

16.

Jones S, Emmerson P, Maynard J, Best J, Jordan S, Williams G . Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C-->T:A mutations. Hum Mol Genet. 2002; 11(23):2961-7. DOI: 10.1093/hmg/11.23.2961. View

17.

Sampson J, Dolwani S, Jones S, Eccles D, Ellis A, Evans D . Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet. 2003; 362(9377):39-41. DOI: 10.1016/S0140-6736(03)13805-6. View

18.

Russell A, Zhang J, Luz J, Hutter P, Chappuis P, Berthod C . Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients. Int J Cancer. 2005; 118(8):1937-40. DOI: 10.1002/ijc.21470. View

19.

Castellsague E, Gonzalez S, Guino E, Stevens K, Borras E, Raymond V . Allele-specific expression of APC in adenomatous polyposis families. Gastroenterology. 2010; 139(2):439-47, 447.e1. PMC: 2910837. DOI: 10.1053/j.gastro.2010.04.047. View

20.

Boparai K, Dekker E, van Eeden S, Polak M, Bartelsman J, Mathus-Vliegen E . Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology. 2008; 135(6):2014-8. DOI: 10.1053/j.gastro.2008.09.020. View